Skip to main content
All Posts By

admin

opgen-logo

OPGEN ANNOUNCES PRICING OF $10 MILLION PRIVATE PLACEMENT

By News Archive

opgen-logo

OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces the pricing of a private placement of units, each unit consisting of one share of common stock and one warrant to purchase 0.75 of one share of common stock, for an aggregate issuance of 9,053,556 shares of common stock and warrants to purchase 6,790,169 shares of common stock. Each unit will be sold at a price of $1.14375 per unit.  The warrants will be exercisable beginning 90 days after the closing of the transaction, have an exercise price of $1.3125 per share of common stock and may be exercised for five years.  The gross proceeds of the offering are $10.355 million.  The Company will use the net proceeds, after payment of offering expenses to support the sales and marketing and continued research and development of the Company’s rapid diagnostic and Acuitas Lighthouse bioinformatics products and services, and for general corporate purposes.

Read More
glycomimetics-logo

GlycoMimetics Doses First Patient in Phase 2 Portion of Clinical Trial of GMI-1271 in Newly Diagnosed Acute Myeloid Leukemia

By News Archive

glycomimetics-logo

GlycoMimetics, Inc. (NASDAQ: GLYC) today announced dosing of the first patient with newly diagnosed acute myeloid leukemia (AML) in the Phase 2 portion of its ongoing Phase 1/2 study evaluating its novel E-selectin antagonist, GMI-1271, combined with chemotherapy. Earlier this month, the company announced it had received Fast Track designation from the U.S. Food and Drug Administration (FDA) for GMI-1271 for treatment of adult patients with relapsed or refractory AML and elderly patients aged 60 years or older with AML. In addition, GlycoMimetics recently announced that the first patient with relapsed or refractory AML has been dosed in the other arm of the Phase 2 portion of this study.

Read More
welldoc-logo

WellDoc®, a Digital Health Technology Leader, Expands Leadership Team with Roster of Seasoned Healthcare Executives

By News Archive

welldoc-logo

Digital health technology leader WellDoc® has expanded its leadership team with two new C-level executives and a key executive director. Healthcare finance veteran Jeff Lehrfeld has joined the company from Magellan Health as Chief Financial Officer (CFO), and senior marketing executive Tara Charvat, MBA, is the company’s new Chief Marketing Officer (CMO), joining from Valeritas. In addition, Christina Hedge is the new Executive Director, Market Access, reporting to Nick Harsh, Vice President, Market Access, who came to WellDoc this Spring.

Read More
brexit-britain-european-union-pixa

UK life sciences industry grapples with new questions from Brexit spanning funding, regulatory landscape – MedCity News

By News Archive

brexit-britain-european-union-pixa

Last week, Great Britain voted to leave the European Union of 28 member states, or “Brexit.” Since the result was announced sterling has fallen to a 31-year low, there has been a record daily drop in  global equity markets and political turmoil has broken out as the UK Prime Minister has said he will step down and the majority of the leadership team of the official opposition party has resigned.

Read More

209th Edition – June 28, 2016

By BHI Weekly Newsletter Archives

emergent-biosolution-logo

Gaithersburg biotech Emergent BioSolutions gets Zika contract worth up to $21.9 million from BARDA – Baltimore Business Journal

By News Archive

emergent-biosolution-logo

Gaithersburg-based Emergent BioSolutions will manufacture one of the first potential vaccines to fight the Zika virus, it announced Monday.

Under a federal contract, Emergent (NYSE: EBS) will develop and manufacture the vaccine for the Biomedical Advanced Research and Development Authority (BARDA), which is part of the U.S. Department of Health and Human Services. Emergent will develop the vaccine material from a base created by an undisclosed private company, university or institution and provided by BARDA, officials said.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.